Business · 10/02/2009Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for MIRCERA Patent Extension
Summary
The FDA has published a notice determining the regulatory review period for MIRCERA, a human biological product, following a patent extension application submitted to the Director of Patents and Trademarks at the US Department of Commerce.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →